Significance of mammalian target of rapamycin in patients with locally advanced stage IV head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil
Authors:
- 27 April 2015
- journal article
- research article
- Published by Wiley in Head & Neck
- Vol. 38 (S1) , E844-E852
Abstract
Background: This study evaluated the significance of mammalian target of rapamycin (mTOR) activation on the prognosis of patients with locally advanced head and neck squamous cell carcinoma (HNSCC) receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil (TPF).Methods: Immunohistochemistry (IHC) for phosphorylated‐mTOR and phosphorylated‐p70 ribosomal S6 protein kinase (p70S6K) examined in 107 patients with locally advanced HNSCC receiving TPF was correlated with treatment outcome. The effect of mTOR inhibition on HNSCC cell lines was investigated in vitro and in vivo.Results: Phosphorylated‐mTOR expression was independently significantly associated with response to TPF, progression‐free survival (PFS), and overall survival (OS). In cell lines and xenograft models, mTOR inhibitor, everolimus, enhanced the effect of docetaxel.Conclusion: In patients with locally advanced HNSCC treated with TPF, phosphorylated‐mTOR expression was independently associated with prognosis. In vitro and in vivo, concomitant inhibition of mTOR enhanced the effect of docetaxel. Our findings suggest the potential of mTOR as a therapeutic target for locally advanced HNSCC. © 2015 Wiley Periodicals, Inc. Head Neck 38: E844–E852, 2016Keywords
Funding Information
- Chang Gung Memorial Hospital (CMRPG8D0681 and CMRPG8B1263, CLRPG871342)
This publication has 29 references indexed in Scilit:
- A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancerCancer, 2013
- Inhibiting the mTOR Pathway Synergistically Enhances Cytotoxicity in Ovarian Cancer Cells Induced by Etoposide through Upregulation of c-JunClinical Cancer Research, 2011
- Phosphorylated mTOR Expression is Associated with Poor Prognosis for Patients with Esophageal Squamous Cell CarcinomaAnnals of Surgical Oncology, 2010
- Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patientsRadiotherapy and Oncology, 2009
- Recent Advances in Head and Neck CancerNew England Journal of Medicine, 2008
- Role of mTOR in anticancer drug resistance: Perspectives for improved drug treatmentDrug Resistance Updates, 2008
- The Efficacy of an Induction Chemotherapy Combination with Docetaxel, Cisplatin, and 5-FU Followed by Concurrent Chemoradiotherapy in Advanced Head and Neck CancerCancer Research and Treatment, 2007
- mTOR and cancer: insights into a complex relationshipNature Reviews Cancer, 2006
- Mammalian Target of Rapamycin, a Molecular Target in Squamous Cell Carcinomas of the Head and NeckCancer Research, 2005
- Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapyEuropean Journal of Cancer, 2005